NXL — Nexalin Technology, Inc.
—
Nasdaq ·
Health Care ·
Health Care Equipment & Supplies ·
CIK 1527352 ·
Last close
$1.50
Market Cap
$1.85M
52W High
$33.60
52W Low
$1.31
ADV30
57,339
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 78,301 | 55,681 | -2,609,297 | -2,662,068 | 3,287,275 | 793,139 | 3,023,933 |
| Jun 2026 | 12,161 | 8,897 | -2,247,315 | -2,239,170 | 3,004,179 | 1,004,958 | 1,484,756 |
| Mar 2026 | 14,950 | 13,133 | -2,119,902 | -2,096,837 | 3,694,633 | 1,207,895 | 808,364 |
| Dec 2025 | 171,895 | 150,866 | -2,413,167 | -2,376,546 | 4,635,319 | 654,783 | 887,333 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-6,128,895
Investing CF
$5,284,197
Financing CF
$1,418,336
CapEx
$-179,862
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.45
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-97,203,419
Inventory
$233,462
Receivables
$52,930
ST Investments
$0
EBIT TTM
$-9,126,015
Pretax Income TTM
$-8,988,864
Interest Exp TTM
—
Analysts
1
Yahoo Snapshot (yfinance, live)
Total Revenue
$217,155
EBITDA
$-9,080,485
Free Cash Flow
$-2,533,424
Enterprise Value
$89,515
Total Cash
$1,004,958
Total Debt
$0
Shares Out
1,236,560
Trailing EPS
$-13.69
Book Value
$5.86
ROE
-240.3%
ROA
-119.2%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 301,647 | -8,390,881 | -8,222,181 | 4,635,319 | 887,333 | 3,747,986 | -4,957,658 |
| Dec 2024 | 168,721 | -7,754,646 | -7,607,182 | 4,222,732 | 546,694 | 3,676,038 | -3,944,390 |
| Dec 2023 | 110,748 | -5,696,296 | -4,648,709 | 3,631,916 | 425,281 | 3,206,635 | -3,835,384 |
| Dec 2022 | 1,321,357 | -1,833,031 | -1,697,816 | 7,432,136 | 1,953,449 | 5,478,687 | -2,215,699 |
TTM Snapshot
Revenues TTM
$217,155
NetIncome TTM
$-8,988,864
OpCashFlow TTM
—
Assets (Latest)
$3,004,179
Forward EPS
$-7.55
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CODX | Co-Diagnostics, Inc. | $2.06M | $0.20 | — |
| VVOS | Vivos Therapeutics, Inc. | $1.60M | $0.08 | — |
| AMIX | Autonomix Medical, Inc. | $2.21M | $1.08 | — |
| CUPR | Cuprina Holdings (Cayman) LTD | $1.56M | $1.69 | — |
| NUWE | Nuwellis, Inc. | $2.22M | $4.10 | — |
News headlines (Yahoo Finance, 1h cache)
Nexalin Technology Announces Fourth Peer-Reviewed Publication in Alzheimer's Disease: 15 mA DIFS™ Significantly Improves Sleep Quality in Patients with Mild Alzheimer's Disease
2026-10-27 13:00 · Yahoo
Nexalin Technology Regains Compliance with Nasdaq Minimum Bid Price Requirement; Nasdaq Hearings Panel Grants Request for Continued Listing
2026-10-08 12:30 · Yahoo
Top Midday Gainers
2026-10-01 18:33 · Yahoo
Nexalin Technology Signs South America Distribution Agreement for Nexalin Sync Commercialization
2026-10-01 14:03 · Yahoo
Nexalin Technology Signs Definitive Exclusive Distribution and Local Manufacturing Agreement for Brazil and South America, Marking a Major Step in its Transition Toward Commercial Revenue Generation
2026-10-01 12:30 · Yahoo
Anixa Biosciences and Nexalin Technology Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV
2026-09-11 13:00 · Yahoo
Nexalin Technology Announces Reverse Stock Split
2026-08-27 11:25 · Yahoo
Nexalin Technology Advances Pivotal Clinical Trial of HALO™ Clarity Toward Q2 2026 Enrollment
2026-04-22 13:35 · Yahoo
Nexalin Announces Peer-Reviewed Publication with Neuroimaging Data in Psychotherapy and Psychosomatics Highlighting Brain-Network Effects and Clinical Improvement in Chronic Insomnia
2026-04-28 13:15 · Yahoo
EXCLUSIVE: Nexalin Brazil Trial Shows Benefits Across Anxiety, Sleep And Quality Of Life
2026-06-10 13:01 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.